John McDonough joined T2 Biosystems in 2007 as the company’s first full-time CEO and President. He has a proven track record driving change, promoting innovation and accelerating growth at industry leading public and private life science and technology companies. At T2 Bio, a medical diagnostic company, he has built the company from inception to a publicly held company with two FDA-cleared products. The initial products are focused on the rapid detection of sepsis, a disease that impacts over 5 million people around the world with a mortality rate of 30 percent. The company’s products have the potential to enable a reduction in mortality by 50 percent.

Prior to joining T2 Bio, John was President of Cytyc Development Corporation where he led acquisition and investment strategies to grow from a single product company with revenue of roughly $300 million in 2003, to revenue of over $750 million with multiple products in 2007. Under his direction, Cytyc acquired five companies totaling over $1 billion and entered into alliances and investments with several early stage companies. Through John’s leadership, Cytyc was acquired by Hologic in 2007, for over $6 billion – almost a 400 percent increase in market cap over a four year period. McDonough, who graduated from Stonehill College in Massachusetts, is on the Board of Directors at Solace Therapeutics and Cytrellis Biosystems. He was a member of the Board of Directors for Interlace Medical, a developer of medical devices for treating gynecological diseases which was acquired by Hologic, Inc. in January, 2011. He was also a member of the Board of Directors of CRi, a developer of optical imaging systems for biomedical research and molecular-based drug and diagnostic development. CRi was acquired by Caliper Life Sciences in December, 2010.

McDonough’s parents were immigrants. His father was from the Aran Islands off Galway and his mother was from Sligo.